Caribou Biosciences (NASDAQ:CRBU) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.44) by 2.27 percent. This is a 6.52 percent increase over losses of $(0.46) per share from the same period last year. The company reported quarterly sales of $2.35 million which beat the analyst consensus estimate of $1.75 million by 34.46 percent. This is a 3.13 percent decrease over sales of $2.43 million the same period last year.